Abstract
The kinetics and dynamics (inhibition of exercise tachycardia) of two controlled-release preparations of propranolol (Elanolol and Inderal LA) were examined in six normal volunteers. Conventional propranolol (Inderal) was also studied for comparison purposes. As compared to conventional propranolol (120 mg), single doses of Elanol (120 mg) and Inderal LA (160 mg) produced a smoother serum level profile, with lower and delayed peak times. Dose-corrected AUC0-24 values were greater after Elanol than after Inderal LA (651 +/- 147 vs 402 +/- 159 ng ml-1 h, means +/- s.e. mean, P greater than 0.05). The profile of inhibition of exercise tachycardia mirrored closely that of the serum levels. At steady state, all regimens studied (Inderal 40 mg three times daily; Elanol 120 mg once daily; Inderal LA 160 mg once daily) ensured relatively sustained serum levels and a stable degree of pharmacological effect. Dose-corrected AUC0-24 values were 797 +/- 148 ng ml-1 h after Inderal, 908 +/- 113 ng ml-1 h after Elanol and 602 +/- 122 ng ml-1 after Inderal LA. The bioavailability of Inderal LA was significantly lower than that of the other preparations. These results demonstrate that long-acting formulations of propranolol can be developed which are not necessarily associated with reduced bioavailability secondary to enhanced first-pass metabolism.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gyselinck P., Remon J. P., Van Severen R., Braeckman P. An improved extraction procedure for the liquid chromatographic determination of propranolol and 4-hydroxypropranolol in plasma. Br J Clin Pharmacol. 1980 Oct;10(4):406–408. doi: 10.1111/j.1365-2125.1980.tb01779.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones G. R., Lazarus J. H., Wynford-Thomas D. A study of long acting propranolol in the early management of hyperthyroidism. Br J Clin Pharmacol. 1981 Dec;12(6):825–828. doi: 10.1111/j.1365-2125.1981.tb01314.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leahey W. J., Neill J. D., Varma M. P., Shanks R. G. Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol. 1980 Jan;9(1):33–40. doi: 10.1111/j.1365-2125.1980.tb04793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mann S., Craig M. W., Balasubramanian V., Raftery E. B. Propranolol LA and ambulatory blood pressure. Br J Clin Pharmacol. 1980 Nov;10(5):443–447. doi: 10.1111/j.1365-2125.1980.tb01786.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McAinsh J., Baber N. S., Smith R., Young J. Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol. 1978 Aug;6(2):115–121. doi: 10.1111/j.1365-2125.1978.tb00835.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Parker J. O., Porter A., Parker J. D. Propranolol in angina pectoris. Comparison of long-acting and standard-formulation propranolol. Circulation. 1982 Jun;65(7):1351–1355. doi: 10.1161/01.cir.65.7.1351. [DOI] [PubMed] [Google Scholar]
- Petrie J. C., Jeffers T. A., Robb O. J., Scott A. K., Webster J. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension. Br Med J. 1980 Jun 28;280(6231):1573–1574. doi: 10.1136/bmj.280.6231.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Routledge P. A., Shand D. G. Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979 Mar-Apr;4(2):73–90. doi: 10.2165/00003088-197904020-00001. [DOI] [PubMed] [Google Scholar]
- Serlin M. J., Orme M. L., MacIver M., Green G. J., Sibeon R. G., Breckenridge A. M. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol. 1983 May;15(5):519–527. doi: 10.1111/j.1365-2125.1983.tb02085.x. [DOI] [PMC free article] [PubMed] [Google Scholar]